COVID-19 pneumonia and tocilizumab use

Authors

DOI:

https://doi.org/10.15381/anales.v81i2.17893

Keywords:

Pneumonia, COVID-19, Interleukin-6, Tocilizumab

Abstract

We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interleukin-6 receptor antagonist (tocilizumab) for compassionate use, obtaining a favorable clinical response.

Downloads

Published

2020-07-03

Issue

Section

Reporte de Casos

How to Cite

1.
Cáceres-Bernaola U, Becerra-Núñez C, Mendívil-Tuchía de Tai S, Ravelo-Hernández J. COVID-19 pneumonia and tocilizumab use. An Fac med [Internet]. 2020 Jul. 3 [cited 2024 Jul. 17];81(2). Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17893